Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
MedImmune LLC
Study ID
NCT02900157
Phase
PHASE1
Status
Completed

Conditions

  • Advanced Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • MEDI9090 — BIOLOGICAL
    MEDI9090 will be administered by IV infusion
  • Durvalumab — BIOLOGICAL
    Durvalumab as a single agent will be administered by IV infusion after patients have completed the prescribed doses of Medi9090.

Study Details

This is an open-label, study of MEDI9090 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of MEDI9090 in adult subjects with advanced solid tumors.

Key Dates

Start date
Aug 9, 2016
Status verified
Jan 2021
Primary completion
Jan 23, 2020
Completion
Jan 23, 2020

Study Design

Enrollment
42 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: MEDI9090

Primary Outcome Measure

Number of subjects reporting infusion related reactions [ Time Frame: First dose of study medication through 30 days after the first dose of study medication ]

Locations (5)

FacilityCityStateZIPSite coordinators
Research SiteScottsdaleArizona85258-
Research SiteLos AngelesCalifornia90025-
Research SiteDenverColorado80218-
Research SiteHuntersvilleNorth Carolina28078-
Research SiteSan AntonioTexas78229-

Find similar trials in Scottsdale, AZ

By research site
Research Site· Scottsdale, AZResearch Site· Los Angeles, CAResearch Site· Denver, COResearch Site· Huntersville, NCResearch Site· San Antonio, TX

Related Studies